These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 33938493)

  • 21. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.
    Huang J; Nair SG; Mahoney MR; Nelson GD; Shields AF; Chan E; Goldberg RM; Gill S; Kahlenberg MS; Quesenberry JT; Thibodeau SN; Smyrk TC; Grothey A; Sinicrope FA; Webb TA; Farr GH; Pockaj BA; Berenberg JL; Mooney M; Sargent DJ; Alberts SR;
    Clin Colorectal Cancer; 2014 Jun; 13(2):100-9. PubMed ID: 24512953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study).
    Nagata N; Maeda H; Ishibashi K; Hirata K; Makiyama A; Iwamoto S; Takemoto H; Imasato M; Yoshida Y; Munemoto Y; Tanaka C; Morita Y; Hotta Y; Toyofuku A; Nagasaka T; Morita S; Sakamoto J; Mishima H
    Med Oncol; 2019 Apr; 36(6):46. PubMed ID: 31020480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study.
    Dote S; Itakura S; Kamei K; Hira D; Noda S; Kobayashi Y; Terada T
    BMC Cancer; 2018 Oct; 18(1):957. PubMed ID: 30290786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial.
    Ballhausen A; Karthaus M; Fruehauf S; Graeven U; Müller L; König AO; von Weikersthal LF; Sommerhäuser G; Jelas I; Alig AHS; Kurreck A; Stahler A; Goekkurt E; Held S; Kasper S; Heinrich K; Heinemann V; Stintzing S; Trarbach T; Modest DP
    ESMO Open; 2024 Jul; 9(7):103628. PubMed ID: 38996519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
    Lévi FA; Boige V; Hebbar M; Smith D; Lepère C; Focan C; Karaboué A; Guimbaud R; Carvalho C; Tumolo S; Innominato P; Ajavon Y; Truant S; Castaing D; De Baere T; Kunstlinger F; Bouchahda M; Afshar M; Rougier P; Adam R; Ducreux M;
    Ann Oncol; 2016 Feb; 27(2):267-74. PubMed ID: 26578731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).
    Aparicio J; Virgili Manrique AC; Capdevila J; Muñoz Boza F; Galván P; Richart P; Oliveres H; Páez D; Hernando J; Serrano S; Vera R; Hernandez-Yagüe X; Gallego RÁ; Riesco-Martinez MC; García de Albeniz X; Maurel J
    Clin Transl Oncol; 2022 Nov; 24(11):2155-2165. PubMed ID: 35761123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer.
    Li C; Gu Y; Zhao M; Yuan Y; Wang F; Wang Z; Li W; Luo H; Chen C; Chen G; Ding P; Wu X; Lu Z; Pan Z; Xu R; He Y; Wan D; Li Y
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1079-87. PubMed ID: 25217393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66.
    Alberts SR; Roh MS; Mahoney MR; O'Connell MJ; Nagorney DM; Wagman L; Smyrk TC; Weiland TL; Lai LL; Schwarz RE; Molina R; Dentchev T; Bolton JS
    J Clin Oncol; 2010 Feb; 28(5):853-8. PubMed ID: 20048179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
    Samaras P; Breitenstein S; Haile SR; Stenner-Liewen F; Heinrich S; Feilchenfeldt J; Renner C; Knuth A; Pestalozzi BC; Clavien PA
    Ann Surg Oncol; 2011 Jul; 18(7):1924-31. PubMed ID: 21207165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol.
    Boilève A; Maillard A; Wagner M; Dromain C; Laurent C; Dupont Bierre E; Le Sourd S; Audemar F; Ulusakarya A; Guerin-Meyer V; Smisth D; Pezzella V; De Baere T; Goere D; Gelli M; Taieb J; Boige V
    BMC Cancer; 2020 Jan; 20(1):74. PubMed ID: 32000724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tian Y; Sidhu R
    Ann Oncol; 2014 Jan; 25(1):107-16. PubMed ID: 24356622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).
    Akiyoshi K; Hamaguchi T; Yoshimura K; Takahashi N; Honma Y; Iwasa S; Takashima A; Kato K; Yamada Y; Onodera H; Takeshita S; Yasui H; Sakai G; Akatsuka S; Ogawa K; Horita Y; Nagai Y; Shimada Y
    Clin Colorectal Cancer; 2018 Mar; 17(1):e83-e89. PubMed ID: 29169974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab.
    Köhne CH; Karthaus M; Mineur L; Thaler J; Van den Eynde M; Gallego J; Koukakis R; Berkhout M; Hofheinz RD
    Drugs R D; 2019 Sep; 19(3):267-275. PubMed ID: 31300973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
    Shi Y; Wan X; Tan C; Li J; Peng L
    Adv Ther; 2020 Feb; 37(2):847-859. PubMed ID: 31902066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
    Goéré D; Benhaim L; Bonnet S; Malka D; Faron M; Elias D; Lefèvre JH; Deschamps F; Dromain C; Boige V; Dumont F; De Baere T; Ducreux M
    Ann Surg; 2013 Jan; 257(1):114-20. PubMed ID: 23235397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
    Focan C; Levi F; Kreutz F; Focan-Henrard D; Lobelle JP; Adam R; Dallemagne B; Jehaes C; Markiewicz S; Weerts J; Bismuth H; Jasmin C; Misset JL
    Anticancer Drugs; 1999 Apr; 10(4):385-92. PubMed ID: 10378673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
    Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
    Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.